­

Results revealed from phase I clinical trial of the first drug to successfully inhibit the MYC gene, which drives many common cancers

01 / 11 / 22|

Omomyc as the first MYC-targeted theraphy to succesfully complete a phase I clinical trial

28 / 10 / 22|

TODAY in El Mundo: “Así avanza el fármaco español pionero en su estrategia contra el cáncer”

26 / 10 / 22|

TODAY in La Vanguardia: “Èxit del primer assaig en pacients del fàrmac Omomyc contra el càncer”

26 / 10 / 22|

EORTC-NCI-AACR (ENA) Symposium 2022 in Barcelona

25 / 10 / 22|

MYC inhibition halts metastatic breast cancer progression by blocking tumor growth, invasion & seeding

21 / 02 / 22|

Peptomyc receives 377.537€ from Spanish Mineco and European Union joint fund

03 / 12 / 21|

PEPTOMYC SL Announces Treatment of First Patient with its Lead Compound OMO-103 in a Phase I/II Clinical Trial

06 / 05 / 21|

Green light by the AEMPS to start clinical trials with OMO-103

16 / 03 / 21|

Peptomyc Board of Directors appoints Giacomo Di Nepi as Chairman of the Board

07 / 01 / 21|